Vericel Corporation has demonstrated robust revenue growth over the past four years driven by its flagship MACI product and expansion into less invasive delivery methods. The company’s commercial, manufacturing, and clinical development strategies focus on enlarging orthopedic and burn care markets. However, regulatory uncertainties, evolving healthcare policies, complex reimbursement environments, and supply dependencies pose ongoing risks. Vericel reported increased profitability and positive operating cash flow in 2025, supporting sustainable operations despite industry headwinds.